Company Overview

BrainsWay Ltd. is a global medical technology company focused on the development and commercialization of non-invasive neuromodulation treatments. The company operates within the medical devices and mental health therapeutics industries, specializing in transcranial magnetic stimulation (TMS). BrainsWay’s core offering is its proprietary Deep TMS technology, designed to stimulate deeper and broader regions of the brain than conventional TMS systems. The company primarily serves psychiatric clinics, hospitals, and research institutions treating patients with major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and other neuropsychiatric conditions.

Founded in 2003, BrainsWay originated as a spinoff from academic research led by its founder, Prof. Abraham Zangen, aimed at improving the clinical efficacy of brain stimulation technologies. The company gradually transitioned from research and development to full commercial operations, achieving multiple regulatory clearances and expanding internationally. BrainsWay is publicly listed on NASDAQ and the Tel Aviv Stock Exchange, reflecting its evolution from an Israel-based research venture into a globally active medtech company.

Business Operations

BrainsWay generates revenue primarily through the sale, lease, and service of its Deep TMS Systems, along with recurring revenue from treatment-related consumables and maintenance agreements. Its main operating segment is the Deep TMS medical device business, which encompasses system manufacturing, clinical support, and post-sale services. The company focuses on FDA-cleared indications, with treatments marketed for depression and OCD, as well as additional indications cleared in other jurisdictions.

Operations are conducted through a combination of direct sales and distributor partnerships. BrainsWay Ltd. conducts most of its North American commercial activity through its wholly owned subsidiary, BrainsWay USA, Inc., while international sales are supported by regional distributors. The company maintains control over its core technology, including proprietary H-Coil designs and associated software, which form the foundation of its competitive differentiation.

Strategic Position & Investments

Strategically, BrainsWay emphasizes expansion of clinical indications, geographic market penetration, and increased utilization of its installed base. Growth initiatives include pursuing additional regulatory approvals, expanding reimbursement coverage, and supporting clinical research to broaden the therapeutic use of Deep TMS. The company has consistently invested in post-market studies and investigator-initiated trials to strengthen clinical evidence and physician adoption.

BrainsWay has not historically pursued large-scale acquisitions, instead favoring organic growth and internal technology development. Its key investments are concentrated in R&D, clinical validation, and commercialization infrastructure. Emerging areas of focus include additional neuropsychiatric and neurological indications, though the pace and scope of expansion depend on regulatory outcomes and clinical trial results.

Geographic Footprint

BrainsWay is headquartered in Israel, with primary operational and R&D activities based there. Its largest commercial market is North America, particularly the United States, where the majority of its revenue is generated. The company also maintains a presence in Europe, Asia-Pacific, and Latin America through distributor networks and strategic partners.

The company’s systems are installed in multiple countries across North America, Europe, and parts of Asia, giving it a diversified international footprint. While Israel remains central to innovation and corporate governance, international markets—especially the U.S.—drive commercial scale and growth.

Leadership & Governance

BrainsWay’s leadership combines academic neuroscience roots with commercial medical device experience. The company continues to emphasize clinical rigor, regulatory compliance, and long-term value creation as part of its governance and strategic vision. Its board and executive team oversee strategy, capital allocation, and global expansion while maintaining close alignment with clinical research priorities.

Key executives include:

• Christopher Von Jako – President and Chief Executive Officer
• Ran Binyamini – Chief Financial Officer
• Prof. Abraham Zangen – Founder and Director
• Daniel Lurie – Chief Business Officer

Leadership philosophy centers on advancing evidence-based mental health treatments while scaling a sustainable, globally competitive medtech platform.